GUTSHIGH SIGNALFINANCIAL10-K

GUTS experienced severe financial deterioration with net losses more than doubling to $141M while stockholders' equity collapsed by 67% to just $9.5M.

The company is burning through cash at an accelerated rate with operating cash flow worsening by 38% to -$90.3M, indicating unsustainable spending relative to its shrinking equity base. Despite raising capital (evidenced by increased cash and references to multiple 2025 offerings), the dramatic equity erosion suggests significant dilution to existing shareholders and potential going concern issues.

Comparing 2026-03-24 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

GUTS shows a company in severe financial distress with losses doubling to $141M while operating cash burn accelerated to over $90M annually. While total assets grew 12% and cash increased 21% (likely from equity raises mentioned in the filing), stockholders' equity plummeted 67% to only $9.5M and liabilities surged 40%, indicating massive shareholder dilution and deteriorating financial position. The combination of accelerating losses, minimal remaining equity, and reduced capital expenditures suggests a company struggling to fund operations and advance its clinical programs.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-105.2%
-$68.7M→-$141.0M

Net income declined 105.2% — review whether driven by operations, interest costs, or non-recurring items.

Capital Expenditure
Cash Flow
-68.4%
$1.8M→$557K

Capex reduced 68.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-66.7%
$28.4M→$9.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Liabilities
Balance Sheet
+40.5%
$79.7M→$111.9M

Liabilities grew 40.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Operating Cash Flow
Cash Flow
-37.9%
-$65.5M→-$90.3M

Operating cash flow fell 37.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Assets
Balance Sheet
+22%
$71.8M→$87.6M

Current assets grew 22% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
+20.9%
$67.5M→$81.5M

Cash grew 20.9% — improving liquidity position supports investment and shareholder returns.

Total Assets
Balance Sheet
+12.3%
$108.1M→$121.4M

Asset base grew 12.3% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-24
PRIOR — 2025-03-03
ADDED
Solely for purposes of this disclosure, shares of common stock held by executive officers, directors and certain stockholders of the registrant as of such date have been excluded because such holders may be deemed to be affiliates.
Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States ( U.S.
References to 2025 and 2024 refer to the year ended December 31, 2025 and the year ended December 31, 2024, respectively.
All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, business strategy (including our Strategic Reprioritization, as defined herein), prospective products, or product candidates, plans regarding or status of clinical trials or studies and their design, our plans for readouts of interim or final results, product approvals, communications with or submissions to the U.S.
Food and Drug Administration (the FDA ), research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management, the anticipated use of or impact of the net proceeds from the ATM Offering, the August 2025 Offering and the September 2025 Offering, and the timing of any of the foregoing are forward-looking statements.
+7 more — sign up free →
REMOVED
Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP.
References to 2024 and 2023 refer to the year ended December 31, 2024 and the year ended December 31, 2023, respectively.
Our Company We are a metabolic therapeutics company focused on breaking the pattern of treatment of metabolic diseases, including obesity and type 2 diabetes ( T2D ).
According to the Centers for Disease Control and the International Diabetes Federation, approximately 100 million people in the United States have prediabetes and/or are living with obesity, and an additional 25 million people have T2D and are on medical therapy.
According to a Kaiser Family Foundation Health Tracking Poll from May 2024, approximately 6% of adults are taking glucagon-like peptide-1 ( GLP-1 ) drugs, translating to approximately 10 million patients on therapies that require chronic administration and do not correct the underlying disease of obesity.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →